Crystal Structure of Human Carboxylesterase 1 Complexed with the Alzheimer's Drug Tacrine from Binding Promiscuity to Selective Inhibition by Bencharit, Sompop et al.
Chemistry & Biology, Vol. 10, 341–349, April, 2003, 2003 Elsevier Science Ltd. All rights reserved. DOI 10.1016/S1074-5521(03)00071-1
Crystal Structure of Human Carboxylesterase 1
Complexed with the Alzheimer’s Drug Tacrine:
from Binding Promiscuity to Selective Inhibition
active forms in vivo, including the cholesterol-lowering
drug lovastatin, and angiotensin-converting enzyme in-
hibitors delapril, imidapril, and temocapril [8, 9]. hCE1
employs the standard two-step serine hydrolase cata-
lytic mechanism involving the formation of an acyl-
Sompop Bencharit,1,2 Christopher L. Morton,4
Janice L. Hyatt,4 Peter Kuhn,5,6 Mary K. Danks,4
Philip M. Potter,4 and Matthew R. Redinbo1,3,*
1Department of Chemistry
2 School of Dentistry
3 Department of Biochemistry and Biophysics and enzyme intermediate at the enzyme’s catalytic serine
[2]. hCE1 shares 47% sequence identity with humanThe Lineberger Comprehensive Cancer Center
University of North Carolina, Chapel Hill intestinal carboxylesterase (hiCE; also called hCE2), a
related esterase that exhibits substrate preferences dis-Chapel Hill, North Carolina 27599
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We have previously reported the first crystal struc-St. Jude Children’s Research Hospital
Memphis, Tennessee 38105 tures of hCE1 in complexes with either the heroin analog
naloxone methiodide or the cocaine analog homatropine5 Stanford Synchrotron Radiation Laboratory
2575 Sand Hill Rd, MS 69 [10]. These structures revealed that hCE1 exhibits the
/-hydrolase fold typical of serine esterases but alsoMenlo Park, California 94025
contains a large substrate binding gorge with both rigid
and flexible pockets. The hCE1 substrate binding gorge
is lined largely by hydrophobic residues which surroundSummary
a serine esterase catalytic triad composed of Ser-221,
His-468, and Glu-354. In addition, we showed that hCE1Human carboxylesterase 1 (hCE1) is a broad-spectrum
bioscavenger that plays important roles in narcotic exists in a trimer-hexamer equilibrium that can be shifted
toward trimer through the binding of compounds to ametabolism, clinical prodrug activation, and the pro-
cessing of fatty acid and cholesterol derivatives. We site on the surface of the enzyme. hCE1 metabolizes
the methyl ester linkage on R-cocaine, and both acetyldetermined the 2.4 A˚ crystal structure of hCE1 in com-
plex with tacrine, the first drug approved for treating groups on heroin to generate 6-acetylmorphine and
morphine [5, 11]. hCE1 is also capable of trans-esteri-Alzheimer’s disease, and compare this structure to
the Torpedo californica acetylcholinesterase (AcChE)- fying cocaine in the presence of ethanol to cocaethyl-
ene, a toxic cocaine metabolite found in humans whentacrine complex. Tacrine binds in multiple orientations
within the catalytic gorge of hCE1, while it stacks in cocaine and alcohol are abused together [12]. trans-
esterification occurs when ethanol attacks the covalentthe smaller AcChE active site between aromatic side
chains. Our results show that hCE1’s promiscuous acyl-enzyme intermediate rather than water. Regulating
hCE1’s activity during situations of narcotic abuse or over-action on distinct substrates is enhanced by its ability
to interact with ligands in multiple orientations at once. dose could provide a novel way to treat these conditions.
hCE1 also appears to be involved in cholesterol traf-Further, we use our structure to identify tacrine deriva-
tives that act as low-micromolar inhibitors of hCE1 ficking and other processes important to cell biology
and human physiology. hCE1 contains fatty acyl ethyland may provide new avenues for treating narcotic
abuse and cholesterol-related diseases. ester (FAEE) synthase activity in which long-chain fatty
acids are trans-esterified with ethanol to generate
FAEEs [13]. The build-up of these toxic compounds inIntroduction
the tissues of alcoholics is a hallmark of the development
of this disease and is thought to play a role in the necroticHuman carboxylesterase 1 (hCE1) is a member of the
serine hydrolase family of enzymes (E.C. 3.1.1.1) and action of ethanol in liver and other organs [14]. hCE1
has also been reported to contain both acyl-coenzymeexhibits low specificity and the ability to act on numer-
ous structurally distinct substrates [1]. hCE1 hydrolyzes A:cholesterol acyl transferase (ACAT) activity [15], which
creates cholesteryl esters, and cholesteryl ester hy-ester, thioester, and amide-ester linkages in a wide vari-
drolase (CEH) activity [16]. These actions are importantety of endogenous and xenobiotic substrates [2, 3]. The
for cholesterol trafficking both within cells and betweenenzyme is expressed in liver, intestine, kidney, lung,
tissues throughout the body. hCE1 was recently foundtestes, heart, monocytes, and macrophages [2–4]. Its
to be one of only three cellular targets bound by thecentral biological role appears to be drug and xenobiotic
anticancer drug tamoxifen, and it was proposed that themetabolism necessary for the chemoprotective func-
physical interaction between tamoxifen and hCE1 maytions of proteins in the liver and other “front-line” defense
mediate the cholesterol-lowering effects of this drug [17].tissues. hCE1 metabolizes numerous human drugs, in-
In additional to its catalytic actions, hCE1 appearscluding cocaine, heroin, meperidine, and lidocaine [5–7].
to be critical to protein retention and release from theThe enzyme also processes several prodrugs to their
endoplasmic reticulum (ER) [18]. hCE1 contains ER tar-
geting and retention sequences at its N and C termini,
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When it traffics to the surface of hepatocytes for secre-search Institute, Scripps PARC Institute, CB227, 10550 North Torrey
Pines Road, La Jolla, California 92037. tion into circulating plasma, hCE1 is one of the proteins
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Figure 1. Chemical Structures of Acridine,
Tacrine, 6,9-Diamino-2-Ethoxyacridine, and
9-Amino-6-Chloro-2-Methoxyacridine, with
the Acridine Numbering System Indicated
the sporozite stage of the Plasmodium falciparum para- the cocaine analog homatropine and the heroin analog
naloxone reported previously, sharing 0.35 and 0.33 A˚site interacts with to gain entrance into liver cells [20].
hCE1 (also called egasyn) complexes with the UDP- rmsd over all equivalent atoms, respectively [10]. Each
hCE1 monomer is composed of a central catalytic do-glucuronysyltransferase (UGT) phase II drug metabolism
enzymes to hold the UGT’s in the ER lumen [21]. hCE1 main, which contains the serine hydrolase catalytic triad,
an - domain, and a regulatory domain (Figure 2A).is also involved in binding to and retaining the C-reactive
protein (CRP) in the ER lumen of human hepatocytes [22]. The active site is located at the base of a 10–15 A˚ deep
catalytic gorge formed at the interface of the three do-CRP responds to infection and cellular damage through-
out the body and was recently identified as a highly mains, and is covered by two loops, 1 and 2, and
two helices, 1 and 10. The enzyme contains twosensitive early marker of cardiovascular disease [23].
Tacrine (9-amino-1,2,3,4- tetrahydroacridine) was the disulfide linkages per monomer (87–116, 274–285), as
well as one high-mannose N-linked glycosylation site atfirst drug approved for the treatment of the symptoms
of Alzheimer’s disease (AD; Figure 1) [24]. Tacrine is a
potent inhibitor (Ki 38 nM) [25, 26] of human acetylcho-
linesterase (hAcChE), another serine hydrolase related Table 1. Crystallographic Statistics for the hCE1-Tacrine
in sequence (30% identity) and structure (1.2 A˚ rmsd Complex
over 532 C positions) to hCE1. The clinical action of
Data Collection
tacrine in alleviating symptoms of AD is thought to occur
Resolution (A˚; highest shell) 25–2.4 (2.42–2.4)by inhibiting hAcChE and prolonging the lifetime of the
Space group P21acetylcholine neurotransmitter in human brain. The ef-
Asymmetric unit one hexamer
fectiveness of this treatment, however, has been chal- Cell constants (A˚, ) a  90.0
lenged by recent clinical studies [27, 28]. b  117.0
We sought to elucidate the differences in ligand bind- c  176.0
  90ing between hCE1, a low-specificity enzyme, and hAc-
  95.7ChE, a high-specificity enzyme, in complex with the
  90same compound. We present the crystal structure of
Total reflections 563,091
hCE1 in complex with tacrine and compare it to the Unique reflections 141,078
Torpedo california AcChE-tacrine complex [29, 30]. Our Mean redundancy 4.0
results show that hCE1 enhances its ligand binding pro- Rsyma (%; highest shell) 8.1 (23.1)
Wilson B factor (A˚2 ) 35.4miscuity by using a large and conformable active site
Completeness (%; highest shell) 99.5 (99.9)that is capable of allowing compounds to dock in several
Mean I/ (highest shell) 14.3 (5.1)different orientations at once. We further describe tacrine
Refinement Statistics
analogs that act as low-micromolar inhibitors of hCE1. Rcrystb (%; highest shell) 16.2 (21.2)
Rfreec (%; highest shell) 20.7 (28.2)
Number protein atoms 24,756
Results Number solvent sites 2,505
Number carbohydrate atoms 176
Overall Structure Number ligand atoms 90
The structure of hCE1 in complex with tacrine was re- a Rsym  	|I 
 I|/	I, where I is the observed intensity and I is
fined to 2.4 A˚ resolution using torsion angle dynamics the average intensity of multiple symmetry-related observations of
and the maximum likelihood target implemented in CNS that reflection.
b Rcryst  	||Fobs| 
 |Fcalc||/	|Fobs|, where Fobs and Fcalc are the observed(Table 1). The asymmetric unit contains one hexamer
and calculated structure factors, respectively.with 32 point group symmetry formed by two stacked
c Rfree  	||Fobs| 
 |Fcalc||/	|Fobs| for 7% of the data not used at anyC3 trimers (Figures 2A and 2B). The hCE1-tacrine trimer
stage of structural refinement.
is similar to the structures of hCE1 in complexes with
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expect that they are the portions of a long glycosylation
site present at each Asn-79. They appear to assist in the
stabilization of the hCE1 trimer by packing into adjacent
monomers in the oligomer.
The hCE1 hexamer is formed by two trimers stacked
together with their substrate binding gorges facing to-
ward one another (Figure 2B). While the hCE1 trimer
buries only 475 A˚2 of solvent-accessible surface area
per monomer, the dimer interface that creates the hex-
amer is more extensive, burying 1900 A˚2 of surface area
per monomer. A critical packing interaction stabilizing
the hexamer is the interdigitation of the1 and2 loops
that creates the “Z site.” In the structure of hCE1 com-
plexed to the cocaine analog homatropine, the Z site
was found to bind to an enantiomeric mixture of homat-
ropine molecules, and these prevent the packing of the
hexamer. Thus, the hCE1-homatropine complex con-
tained only trimers in the asymmetric unit [10]. In the
hCE1-tacrine structure, however, the Z site is not filled
by ligand, but instead forms a dimeric interface critical
to creating the hCE1 hexamer.
Interpreting Electron Density at the Active Site
hCE1 was crystallized in the presence of 100-fold molar
excess tacrine. After structural refinement of the protein,
carbohydrate, and solvent models was complete, we
calculated 2.4 A˚ resolution simulated annealing (SA)
omit maps at the active site of each hCE1 monomer. It
was clear from these electron density maps that tacrine
was bound within each substrate binding gorge (Figure
3). The density at the active sites was planer and of
roughly the correct size and shape for the planer tacrine
ligand. It was also clear, however, that tacrine was pres-
ent in multiple orientations at each active site. When
single orientations of tacrine were placed within SA omit
density, they did not fill all the electron density preset.
Further, when these single orientations were refined,
positive difference electron density peaks of 5–8  ap-
peared, indicating the presence of additional atoms at
each active site. When water molecules were found to be
insufficient to satisfy this difference density, we pursued
Figure 2. Structure of the Human Carboxylesterase 1-Tacrine the placement of additional tacrine ligands at each ac-
Complex
tive site. We used a combination of SA omit density,
(A) A trimer of hCE1 (MOL1, MOL2, and MOL3) complexed with
difference density, and the program Blob, which usestacrine viewed down the 3-fold axis of symmetry and into the cata-
a Monte Carlo algorithm to place ligands into electronlytic gorge of each monomer. The catalytic domains,  domains,
density, to interpret the density at each active site [31].and regulatory domains of each monomer are in blue, green, and
red, respectively, the novel  loops are in orange, the N-acetylglu- The density in some monomers was clearer than in oth-
cosamines (NAG) are in cyan, and the sialic acids (SIA) are in dark ers. For example, monomers 1 and 4 indicated that the
green. 9 amino group on tacrine can be placed up away from
(B) A molecular surface representation of the hCE1 hexamer with
the catalytic Ser-221 residue (Figures 3A and 3D), whilea ribbon representation of one pair of dimers within the hexamer
in monomers 2 and 6 this placement of the 9 aminosuperimposed. The hCE1 hexamer is formed by the stacking of two
group was not observed (Figures 3B and 3F).trimers with their active sites facing in. The hCE1 monomers are
labeled MOL1 to MOL6. We placed four or five tacrine molecules per protein
monomer in our final model: monomer 1 has four ta-
crines (Figure 3A), monomer 2 has four tacrines (Figure
3B), monomer 3 has five tacrines (Figure 3C), monomer 4Asn-79. One or two N-acetylglucosamines (NAG) were
traced at each of the six glycosylation sites in the asym- has five tacrines (Figure 3D), monomer 5 has five tacrines
(Figure 3E), and monomer 6 has four tacrines (Figure 3F).metric unit. In addition, in three of the six monomers, a
sialic acid moiety (SIA) was identified and found to pack Note that the tacrine ligand has pseudo 2-fold symmetry
perpendicular to the molecule’s long axis, which relatesagainst the N terminus of 7 in an adjacent monomer
in the hCE1 trimer. Although these SIA moieties are not the aromatic and nonaromatic rings of the compound
(Figure 1). This was one source of the ambiguity in ta-connected to the NAGs by clear electron density, we
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Figure 3. 2.4 A˚ Resolution Simulated Annealing Omit Maps (Contoured at 3.0 ) Showing the Electron Density for Tacrine Bound at Each
Active Site of the hCE1 Hexamer
The C, C, and O atoms of the catalytic Ser-211 residue are also shown in each panel. We identified four tacrine binding conformations
in monomers 1 ([A]; MOL1), 2 ([B]; MOL2), and 6 ([F]; MOL6), and five tacrine binding conformations in monomers 3 ([C]; MOL3), 4 ([D]; MOL4),
and 5 ([E]; MOL5).
crine’s binding to the hCE1 active site. It was difficult at the 10 position of tacrine forms a hydrogen bond with
the side chain of the catalytic Ser-221 residue (Figureto judge whether the nonaromatic ring was to be to the
left or the right of Ser-221 (as viewed in Figure 3). In 4). The primary amine contacts Ser-221 in 16 of the 27
observed binding modes, while the secondary amineaddition, tacrine has a secondary amine (at the 10 posi-
tion) that serves as a hydrogen bond acceptor and a contacts it in the remaining 11 modes (Figures 3 and
primary amine (at the 9 position) that serves as a hydro- 4). Second, the position of the polar nitrogen group of
gen bond donor. Because Ser-221 acts as both a hydro- tacrine is somewhat variable depending on the binding
gen bond donor and acceptor, it was difficult to interpret mode, shifting by up to 3 A˚ between binding modes but
whether the primary or secondary amine lay adjacent always maintaining hydrogen bond distance from Ser-
to this polar residue at the active site. This generated a 221 (Figures 3 and 4). It can be said that tacrine appears
second ambiguity in tacrine’s binding to hCE1, although to “float” around Ser-221 within the hCE1 active site.
Ser-221 forms hydrogen bonds of between 2.5–3.7 A˚ For this reason, the noncentral rings of tacrine can adopt
long with either the primary or secondary amines in several positions within the substrate binding pocket.
all the tacrine binding modes identified. Each of these The ensemble of tacrines is butterfly shaped in several
factors played a role in the placement of a constellation active sites, and these assemblies fill the large hCE1
of ligands into the SA omit electron density at the active binding gorge more effectively than a single ligand orien-
sites of hCE1 monomers. Our final model of describing tation would (Figures 3 and 4). The relatively nonpolar
the binding of four or five tacrine molecules per enzyme rings of tacrine contact hydrophobic amino acid side
appears to validate effectively the ligand interaction, as chains that line the substrate binding gorge of hCE1.
no difference electron density peaks less than 
1.0  Residues that interact with these regions of tacrine in-
or greater than 2.0  were present after refinement. clude Leu-97, Phe-101, Leu-255, Leu-318, Leu-358, Leu-
363, Met-364, Leu-388, Met-425, and Phe-426. These
rings are observed to dock within both the small, rigidTacrine Binding at the hCE1 Active Site
pocket of hCE1’s active site (adjacent to Phe-101), andIn spite of the multiple binding modes observed for ta-
the large, flexible pocket (adjacent to Leu-255) [10]. Thecrine in each hCE1 monomer, the ligands make several
ability of hCE1 to allow tacrine to dock in multiple orien-contacts conserved in all six active sites. First, either
the 9 amino primary amine or the secondary ring amine tations at once is likely due to several factors, including
Tacrine-Based Inhibitors of Human Carboxylesterase 1
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improve binding affinity [25, 26, 29, 30]. Further, AcChE
tacrine binding site is 6 A˚ from that in hCE1 (the distance
between the 9 amino positions was measured). Thus,
hCE1 and AcChE bind to tacrine in distinct ways and
using discrete binding pockets in each case. These ob-
servations explain why tacrine is a nanomolar affinity
inhibitor of AcChE and does not inhibit hCE1 up to con-
centrations of 100 M.
Selective, Tacrine-Based Inhibitors of hCE1
Selective hCE1 inhibitors will be useful tools to examine
the function of this enzyme in vitro and in vivo. Based
on our crystal structure of hCE1 in complex with tacrine,
we hypothesized that the presence of small substituent
groups at the 2 and 6 positions of tacrine would improve
the binding affinity of the compound for hCE1 (Figure
5B). We identified two commercially available analogs
of tacrine that contain substitutions on the 2 and 6
positions: 6,9-diamino-2-ethoxyacridine and 9-amino-Figure 4. Four Binding Modes of Tacrine Bound within the Catalytic
6-chloro-2-methoxyacridine (Figure 1). These com-Pocket of hCE1 MOL1
pounds are based on the acridine scaffold, which isThe protein residues that line this catalytic pocket are in light blue,
identical to tacrine except that all rings are aromatic.along with the catalytic residues (labeled in bold). The molecular
surface of the catalytic binding pocket is rendered in transparent We examined the inhibitory effects of these compounds
purple. and tacrine on hCE1, hAcChE, and hiCE. hiCE (also
called hCE2) shares 47% sequence identity with hCE1,
is present largely in intestine and liver, and exhibits pref-
the enzyme’s large binding pocket, tacrine’s relatively erences for distinct substrates relative to hCE1. We
small size, and its pseudo-symmetry. found that whereas tacrine is not an inhibitor of hCE1,
6,9-diamino-2-ethoxyacridine and 9-amino-6-chloro-
Comparison between Tacrine Binding to hCE1 2-methoxyacridine inhibited hCE1 with Ki’s of 17.1 and
and AcChE 5.8 M, respectively (Table 2). This represents an im-
We compared structure of tacrine complexed with the provement of 10-fold over tacrine’s ability to inhibit
Torpedo californica (eel) acetylcholinesterase (AcChE) hCE1. We further found that 6,9-diamino-2-ethoxyacrid-
[29, 30] to the hCE1-tacrine complex. hCE1 and AcChE ine and 9-amino-6-chloro-2-methoxyacridine served as
both exhibit the / hydrolase fold common to serine weaker inhibitors of hAcChE relative to tacrine (Table
hydrolases, and share 38% sequence identity and 1.23 A˚ 2). This was expected because there appears to be little
rmsd over 429 equivalent C positions (Figure 5A). The room for these substituent groups in the AcChE sub-
most significant structural differences between the two strate binding gorge. Neither tacrine, 6,9-diamino-2-
enzymes occur in two regions—at the putative “back ethoxyacridine nor 9-amino-6-chloro-2-methoxyacri-
door” region of AcChE and within the substrate binding dine inhibited hiCE (Table 2), further supporting the con-
gorge. The “back door” was proposed to be a secondary clusion that this enzyme is distinct from hCE1 in its
product exit site for the AcChE’s and to be gated by substrate binding gorge [4]. In summary, we show that
Trp-84 on the catalytic domain of the enzyme [32, 33]. the addition of small, substituent groups onto the tacrine
hCE1 places a Phe-101 perpendicular to the position of scaffold produce selective, low-micromolar inhibitors of
Trp-84 in AcChE, effectively blocking the back door hCE1.
in hCE1.
At the active site, the serine hydrolase catalytic triads
of both enzymes line up well (Figure 5B). However, hCE1 Discussion
creates a larger substrate binding gorge that packs
within a distinct region of the enzyme relative to AcChE. Variation in cholesterol trafficking at the blood-brain bar-
rier has been shown to be an important factor in theAs described above, hCE1’s binding gorge is lined by
hydrophobic and, in some cases, mobile amino acid development of Alzheimer’s disease [34]. Because hCE1
appears to play a role in cholesterol trafficking [13, 15],side chains [10], and allows tacrine to bind in up to
five orientations at once. AcChE, in contrast, frames a we sought to examine the enzyme’s ligand binding pro-
miscuity and to identify novel hCE1 inhibitors usefulsmaller ligand binding pocket with largely aromatic side
chains, including Trp-84, Tyr-121, Trp-279, Phe-290, for both in vitro and in vivo studies. We found using
combined crystallographic and biochemical studies thatPhe-330, Phe 331, Tyr-334, and Trp-432 (Figure 5B).
AcChE docks tacrine in a single, specific orientation hCE1 allows tacrine to bind within its large substrate
binding gorge in multiple orientations at once, that hCE1between Trp-84 and Phe-330, two aromatic side chains
conserved in all AcChE enzymes examined to date. Tac- and AcChE bind to tacrine in distinct ways, and that
simple tacrine analogs are selective hCE1 inhibitors.rine largely fills the available space in the AcChE binding
pocket, offering room for small substituent groups that Similar structural and biochemical studies may allow
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Figure 5. Human Carboxylesterase 1 and Acetylcholinesterase
(A) The hCE1-tacrine complex superimposed on the Torpedo californica AcChE-tacrine complex (magenta; PDB code 1ACJ). hCE1 (MOL1)
is colored by domains as in Figure 2A, with the bound tacrine in yellow.
(B) Stereoview of the catalytic gorges of hCE1 and Torpedo californica AcChE superimposed. The molecular surface of ligand binding cavities
of hCE1 and AcChE are rendered in transparent cyan and purple, respectively. The catalytic triad of hCE1 (green) and AcChE (magenta)
superimpose well. The residues lining the hCE1 binding cavity (light blue) are largely hydrophobic and aliphatic, while those lining the AcChE
binding cavity (purple) are aromatic. Note that the shapes of the binding cavities and the locations of the ligands within them are distinct. In
the hCE1 structure, tacrine (cyan) contacts aliphatic residues and forms one hydrogen bond with the enzyme’s catalytic serine. In AcChE,
however, tacrine (light purple) stacks between Trp-84 and Phe-330.
the design of novel compounds for the management of tacrines have been identified that inhibit hAcChE [24,
35–37]. Among the most elaborate are the bis-tacrinescholesterol homeostasis in humans.
The tacrine scaffold has been extensively examined in which two tacrine compounds are linked by six to
eight carbons between the 9 amino positions [36]. Theseusing structure-activity relationships, and several novel
Tacrine-Based Inhibitors of Human Carboxylesterase 1
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Table 2. Selective Inhibition of Human Carboxylesterase 1
hCE1 hiCE AcChE
Tacrine 100 M 100 M 6.9 nM
6,9-diamino-2-ethoxyacridine 17.1 M 100 M 0.49 M
9-amino-6-chloro-2-methoxyacridine 5.8 M 100 M 49 nM
Ki values for the inhibition of hCE1, hiCE, and human AcChE by the compounds listed.
compounds (which are not commercially available) in- metabolism, the activation of clinical prodrugs, and
the processing of fatty acid and cholesterol derivativeshibit hAcChE by placing two tacrines within the catalytic
gorge of the enzyme, one at the base (cation- site) in liver and other tissues. Tacrine (9-amino-1,2,3,4-
tetrahydroacridine) is a potent inhibitor of human ace-and one at the rim (peripheral site) [38]. The protein dimer
essential to the hCE1 hexamer positions the catalytic tylcholinesterase (hAcChE), an enzyme related in
structure and mechanism to hCE1, but does not inhibitgorges of hCE1 in close proximity, only 3–4 A˚ apart
or 36 A˚ between the catalytic Ser-221 of the dimeric hCE1 up to 100 M. To unravel differences in ligand
binding between the low-specificity hCE1 and high-partners (Figure 2B). It would be of interest to examine
the effect that bis-tacrines connected by linkers of specificity AcChE enzymes, we determined the 2.4 A˚
crystal structure of hCE1 in complex with tacrine (using30–40 A˚ would have on the activity and oligomerization
state of hCE1. It is possible that such compounds will 10 mM concentrations of the drug) and compare this
structure to the Torpedo californica AcChE-tacrine com-be inhibitors of hCE1 and will shift the hCE1 trimer-
hexamer equilibrium toward hexamer, allowing one to plex. hCE1 allows tacrine to bind in multiple orienta-
tions within the large active site of each protein mono-examine the impact hCE1 activity and oligomerization
state have on various biological functions. mer in the hCE1 hexamer. Tacrine docks within the
center of the hCE1 catalytic gorge and is contactedhCE1 joins other proteins and enzymes that are pro-
miscuous in terms of either ligand or substrate binding. by several hydrophobic side chains, while it stacks in
the smaller AcChE active site between two aromaticPromiscuous proteins of known structure include rabbit
cytochrome P450 2C5 (CYP2C5) [39], the human xenobi- side chains. A high concentration of the tacrine was
required to visualize the drug bound to the enzyme.otic nuclear receptor PXR [40], and the bacterial quorum
sensor (QacR) [41]. The latter two proteins are tran- However, using our structure, we identify two acridine
analogs, which are related in structure to tacrine, andscriptional regulators that act as front-line detectors of
xenobiotic stress, while CYP2C5 performs oxidative me- show that they act as low-micromolar inhibitors of
hCE1. The development of selective inhibitors of hCE1tabolism on structurally distinct compounds including
progesterone and several steroid compounds. Certain may provide new avenues for treating narcotic abuse
and cholesterol-related diseases.elements common to each of these proteins help to
identify characteristics involved in ligand binding pro-
Experimental Proceduresmiscuity. First, hCE1, PXR, CYP2C5, and QacR all allow
ligand to bind in multiple orientations at once, or to
Protein Purification and Crystallizationseveral sites on the protein. Second, each protein uses
A secreted, 62 kDa form of hCE1 was expressed using baculovirus
a large and structurally flexible ligand binding pocket in Spodoptera frugiperda Sf21 cells and purified as described [42,
that expands the chemical space it can sample. Indeed, 43]. hCE1 was concentrated to 3 mg ml
1 in 50 mM HEPES (pH 7.4)
and crystallized in the presence of 10 mM tacrine using sitting dropthese binding pockets appear to encourage the shuffling
vapor diffusion at 22C. Crystals of 200–300 m in size grew in 10%of ligand-protein interactions to enable the binding of
PEG-3350, 0.4 M Li2SO4, 0.1 M NaCl, 0.1 M LiCl, 0.1 M citrate (pHmultiple ligand orientations simultaneously. Third, be-
5.5), and 5% glycerol, and were cryo-protected in 15% sucrose pluscause CYP2C5, PXR, and hCE1 tend to bind to hy-
mother liquor prior to flash cooling in liquid nitrogen.
drophobic ligands, each protein lines their ligand bind-
ing pocket with largely hydrophobic side chains, but Structure Determination and Refinement
also offers a few polar residues to allow for hydrogen Diffraction data were collected at Stanford Synchrotron Radiation
Laboratory (SSRL) beamline 9-1 at 100 K using cryo-cooled crystalsbonds. In general, these proteins appear to favor hy-
and were processed and reduced using HKL2000 [44]. The hCE1-drophobic, van der Waals, and hydrogen bonding inter-
tacrine complex structure was determined by molecular replace-actions over electrostatic contacts when possible.
ment (AMoRe) [45] using the 2.8 A˚ structure of hCE1 in complex
Taken together, these characteristics help to elucidate with the cocaine analog homatropine (RCSB code 1MX5) [10] as
some of the ways proteins may have sacrificed binding a search model. The structure was refined without carbohydrate
affinity and selectivity for the broader spectrum ability groups, ligands, or waters using torsion angle dynamics in CNS [46]
with the maximum likelihood function target, and included an overallto recognize and act on numerous structurally distinct
anisotropic B factor and a bulk solvent correction. Seven percentcompounds. hCE1 appears to employ this substrate
of the observed data were set aside for cross-validation using freebinding promiscuity for both chemoprotective functions
R prior to any refinement. Noncrystallographic symmetry restraints
and endogenous roles in several biological processes. were employed at initial refinement stages and then removed such
that each monomer was refined independently. Manual adjustments
were performed using the program O [47] and A-weighted [48]Significance
electron density maps. N-linked glycosylation sites were traced in
all monomers. Simulated annealing difference density of 4  fre-
Human carboxylesterase 1 (hCE1) is a broad-spectrum quently indicated the presence of an additional sialic acid sugar
moiety located 4–7 A˚ from the first N-acetylglucosamines of thebioscavenger that plays important roles in narcotic
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N-linked glycosylation sites at Asn-79. These sialic acid sugars are roles in the hepatic metabolism of retinol. Annu. Rev. Nutr. 18,
259–276.not connected by clear density to the carbohydrate chain; however,
they appear to stabilize the hCE1 trimer by packing against a neigh- 4. Satoh, T., Taylor, P., Bosron, W.F., Sanghani, S.P., Hosokawa,
M., and La Du, B.N. (2002). Current progress on esterases: fromboring protein monomer.
Simulated annealing difference density maps indicated the pres- molecular structure to function. Drug Metab. Dispos. 30,
488–493.ence of multiple orientations of tacrine within the active sites of
each hCE1 monomer (Figure 4). The program Blob [31], which fits 5. Kamendulis, L.M., Brzezinski, M.R., Pindel, E.V., Bosron, W.F.,
and Dean, R.A. (1996). Metabolism of cocaine and heroin isligands into experimental electron density, was used to guide the
placement of additional orientations of tacrine molecules. Three of catalyzed by the same human liver carboxylesterases. J. Phar-
macol. Exp. Ther. 279, 713–717.six monomers contain four tacrine orientations, and the remaining
three monomers contain five tacrine orientations. Final structures 6. Zhang, J., Burnell, J.C., Dumaual, N., and Bosron, W.F. (1999).
Binding and hydrolysis of meperidine by human liver carboxyl-exhibit good geometry with no Ramachandran outliers. Molecular
graphic figures were created with MolScript [49], BobScript [50], esterase hCE-1. J. Pharmacol. Exp. Ther. 290, 314–318.
7. Alexson, S.E., Diczfalusy, M., Halldin, M., and Swedmark, S.Raster3D [51], and Dino (www.dino3d.org).
(2002). Involvement of liver carboxylesterases in the in vitro
metabolism of lidocaine. Drug Metab. Dispos. 30, 643–647.Enzyme Inhibition Assays
8. Tang, B.K., and Kalow, W. (1995). Variable activation of lovas-Carboxylesterases
tatin by hydrolytic enzymes in human plasma and liver. Eur. J.Determination of Ki values was performed for the CEs using 3 mM
Clin. Pharmacol. 47, 449–451.o-nitrophenyl acetate as a substrate. Briefly, inhibition constants
9. Takai, S., Matsuda, A., Usami, Y., Adachi, T., Sugiyama, T.,were calculated by assessment of the reduction in the formation of
Katagiri, Y., Tatematsu, M., and Hirano, K. (1997). Hydrolytico-nitrophenol, as monitored by a spectrophotometric assay at 420
profile for ester- or amide-linkage by carboxylesterases pI 5.3nm, using purified hCE1 and hiCE [42, 52, 53]. Reactions were per-
and 4.5 from human liver. Biol. Pharm. Bull. 20, 869–873.formed in 96-well plates in a total volume of 200 l of 50 mM HEPES
10. Bencharit, S., Morton, C.L., Xue, Y., Potter, P.M., and Redinbo,(pH 7.4), and data was recorded at 15 s intervals for up to 5 min.
M.R. (2003). Structural basis of cocaine and heroin metabolismAll reactions were performed in duplicate, and at least eight concen-
by a promiscuous human drug-processing enzyme. Nat. Struct.trations of inhibitor were used to determine Ki constants. Enzyme
Biol., in press.velocity values versus inhibitor concentrations were plotted, and Ki
11. Brzezinski, M.R., Spink, B.J., Dean, R.A., Berkman, C.E., Cash-values were calculated from sigmoidal curve fits using GraphPad
man, J.R., and Bosron, W.F. (1997). Human liver carboxylester-Prism software and established methods [54]. Routinely all curve
ase hCE-1: binding specificity for cocaine, heroin, and theirfits demonstrated r2 values of 0.95 or greater.
metabolites and analogs. Drug Metab. Dispos. 25, 1089–1096.Acetylcholinesterase
12. Brzezinski, M.R., Abraham, T.R., Stone, C.L., Dean, R.A., andPurified human acetylcholinesterase (hAcChE) was purchased from
Bosron, W.F. (1994). Purification and characterization of a hu-Sigma (C-0663, amphiphilic form purified from human erythrocytes)
man liver cocaine carboxylesterase that catalyzes the produc-in 20 mM HEPES (pH 8.0) containing 0.1% Triton X-100, was stored
tion of benzoylecgonine and the formation of cocaethylene fromat 4C, and was diluted in 50 mM HEPES (pH 7.4) immediately before
alcohol and cocaine. Biochem. Pharmacol. 48, 1747–1755.performing assays. The inhibition of hAcChE was determined using
13. Diczfalusy, M.A., Bjorkhem, I., Einarsson, C., Hillebrant, C.G.,a 96-well plate assay based upon the original method described by
and Alexson, S.E. (2001). Characterization of enzymes involvedEllman [55, 56]. Reactions were performed in a total volume of 200
in formation of ethyl esters of long-chain fatty acids in humans.
l of 50 mM HEPES (pH 7.4) containing 1 mM acetylthiocholine, 0.5
J. Lipid Res. 42, 1025–1032.mM 5,5-dithio-bis(2-nitrobenzoic acid), 0.45 U/ml hAcChE (amphi-
14. Nanji, A.A., Su, G.L., Laposata, M., and French, S.W. (2002).philic form isolated from human erythrocytes), and appropriate con-
Pathogenesis of alcoholic liver disease–recent advances. Alco-centrations of inhibitor. Absorbance at 405 nM was determined at
hol. Clin. Exp. Res. 26, 731–736.15 s intervals for up to 2 min. All data analyses were performed in
15. Becker, A., Bottcher, A., Lackner, K.J., Fehringer, P., Notka, F.,
duplicate using a minimum of eight concentrations of inhibitor, and
Aslanidis, C., and Schmitz, G. (1994). Purification, cloning, and
Ki values were calculated in an identical fashion to that described
expression of a human enzyme with acyl coenzyme A: choles-
above. R2 values for the curve fits exceeded 0.95.
terol acyltransferase activity, which is identical to liver carboxyl-
esterase. Arterioscler. Thromb. 14, 1346–1355.
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